Histone deacetylases (HDACs) have long been recognized as pivotal regulators of chromatin remodeling and gene expression, with aberrations in their activity implicated across numerous cancers. Among these, HDAC4 has emerged as a particularly promising target due to its multifaceted role in modulating cellular survival and stress responses. Traditional HDAC inhibitors, while effective to some extent, often suffer from a lack of isoform specificity and associated toxicities. The advent of PROTAC (Proteolysis Targeting Chimera) technology offers a transformative avenue by harnessing the cell’s own ubiquitin-proteasome system to selectively degrade target proteins, thereby overcoming limitations observed with mere enzymatic inhibition.

The research team engineered a sophisticated PROTAC molecule designed to recognize and bind HDAC4 selectively, recruiting E3 ubiquitin ligases to tag HDAC4 for proteasomal degradation. This precision targeting eliminates HDAC4 protein function more completely than traditional inhibitors. Detailed biophysical and biochemical assays confirmed the degrader’s specificity and potency, setting the stage for subsequent cellular and in vivo studies. These investigations demonstrated that HDAC4 depletion precipitates significant biological effects in lung cancer cells, reshaping their response to external stimuli such as radiation.

Central to this study is the previously underappreciated interaction between HDAC4 activity and ferroptosis—a unique form of regulated cell death characterized by iron-dependent lipid peroxidation. Ferroptosis has garnered intense research interest due to its distinct biochemical pathways and potential to overcome apoptosis resistance in cancer cells. By delineating the molecular crosstalk by which HDAC4 influences ferroptotic machinery, the researchers revealed that HDAC4 acts as a suppressor of ferroptosis, thereby facilitating cancer cell survival under genotoxic stress, including radiation exposure.

The application of the HDAC4-specific PROTAC degrader in lung cancer models precipitated a dramatic increase in ferroptotic cell death upon radiation treatment. Mechanistic dissections elucidated that proteolytic removal of HDAC4 disrupts key antioxidant defenses and lipid metabolic pathways, culminating in the accumulation of lethal lipid peroxides. This biochemical vulnerability acts synergistically with radiation-induced reactive oxygen species, culminating in enhanced cancer cell eradication. Importantly, this ferroptosis-driven radiosensitization occurs without compromising normal tissue integrity, highlighting the degrader’s therapeutic index.

Beyond mono-therapeutic efficacy, combinatorial strategies integrating the HDAC4 degrader and radiation therapy exhibited profound tumor growth inhibition in murine lung cancer xenografts. These preclinical models substantiated the molecular findings, demonstrating reduced tumor burden and prolonged survival. The targeted depletion of HDAC4 rendered even radioresistant tumor subsets markedly more susceptible, suggesting broad applicability of this approach across heterogeneous lung cancer phenotypes.

This study also navigated the complex interplay between epigenetic regulation and ferroptosis, shedding light on how chromatin state and transcriptional programs governed by HDAC4 orchestrate ferroptotic sensitivity. Chromatin immunoprecipitation coupled with transcriptomic analyses revealed that HDAC4 modulates expression of key ferroptosis regulators, antioxidant enzymes, and iron metabolism genes. The PROTAC-mediated degradation precipitated epigenetic shifts favoring an oxidative stress-prone environment, thereby tipping the cellular equilibrium towards ferroptotic demise.

At a molecular level, the researchers scrutinized the downstream signaling cascades impacted by HDAC4 loss. Notably, enhanced lipid peroxidation was attributable to impaired expression of glutathione peroxidase 4 (GPX4), a central ferroptosis inhibitor. In tandem, disrupted iron homeostasis further exacerbated redox imbalance, fostering the inception of ferroptosis. These insights underscore the multi-tiered regulatory role of HDAC4 at metabolic and transcriptional fronts, providing a compelling rationale for its selective targeting.

The innovation of employing a PROTAC modality for HDAC4 stands as a testament to the emerging paradigm in drug discovery that transcends mere inhibition. By eliciting degradation, PROTACs redefine target modulation, offering durable and tunable effects with potential for reduced resistance. This approach exemplifies how precision chemical biology can interrogate and manipulate complex oncogenic machineries with unprecedented specificity and effectiveness.

From a clinical perspective, the implications are profound. Lung cancer remains among the deadliest malignancies worldwide, with resistance to standard therapies posing a major challenge. Radiation therapy, though widely used, often encounters limitations due to tumor cell resilience. The integration of HDAC4-specific PROTAC degraders could revolutionize radiotherapy protocols, transforming resistant tumors into vulnerable targets through ferroptosis induction. Prospective clinical trials informed by these findings may unlock new therapeutic windows and improve patient outcomes markedly.

Furthermore, the study catalyzes broader exploration of ferroptosis as an exploitable vulnerability in cancer therapeutics. The identification of epigenetic regulators as ferroptosis gatekeepers invites investigation into other HDAC family members and associated chromatin modulators. Expanding the arsenal of PROTACs against such targets might yield a new class of radiosensitizers and combinatorial cancer treatments with wider applicability beyond lung cancer.

The research also foregrounds potential biomarkers for patient stratification and monitoring treatment response. The expression levels and functional status of HDAC4, along with ferroptosis-related gene signatures, could guide precision medicine strategies, ensuring that PROTAC-based interventions are deployed where they hold maximal efficacy. Such personalized approaches embody the evolving landscape of oncology, where molecular insights converge with therapeutic innovation.

Nevertheless, challenges remain before clinical translation. The optimization of PROTAC pharmacokinetics, delivery, and potential off-target effects requires thorough evaluation. Long-term safety profiles in relevant models will determine feasibility, particularly given the critical roles of HDACs in normal physiology. Collaborative efforts spanning chemical biology, oncology, pharmacology, and clinical research will be essential to navigate these complexities.

In summary, the pioneering work developing an HDAC4-specific PROTAC degrader unveils a powerful mechanism to sensitize lung cancer cells to radiation via ferroptosis enhancement. This strategy exemplifies the confluence of targeted protein degradation technology with an emerging cell death paradigm, forging a path towards next-generation cancer therapies. As the molecular underpinnings of ferroptosis and epigenetic regulation continue to unravel, such interventions promise to transform the therapeutic landscape and extend hope to patients facing formidable malignancies.

Subject of Research:
HDAC4-targeted protein degradation for enhancing radiation therapy efficacy in lung cancer through ferroptosis induction.

Article Title:
An HDAC4-specific PROTAC degrader achieves radiation sensitization by enhancing ferroptosis in lung cancer.

Article References:

Cheng, C., Sun, L., Yang, J. et al. An HDAC4-specific PROTAC degrader achieves radiation sensitization by enhancing ferroptosis in lung cancer. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73682-0

Image Credits: AI Generated

Intrinsic to the survival and proliferation of cancer cells is their ability to subvert or develop resistance to chemotherapy drugs. Traditional proteolysis targeting chimeras, or PROTACs, have sought to harness the cell’s natural recycling machinery—the ubiquitin–proteasome system—to tag and degrade deleterious proteins. However, conventional PROTACs rely on a multistep tagging mechanism that begins with the attachment of ubiquitin molecules to the target protein, a process fraught with inefficiencies and variabilities dependent on specific cellular contexts. These limitations have inspired the search for alternative, more direct methods of inducing protein degradation.

The ubiquitin–proteasome pathway acts as a fundamental cellular waste disposal system, where damaged or superfluous proteins are marked with ubiquitin tags. These tags act as molecular signals, directing the proteins toward the proteasome—the cellular organelle responsible for their breakdown and recycling. Many pathological conditions, including cancer, exploit or evade this system, presenting both hurdles and opportunities for therapeutic intervention. The research spearheaded by Bernat Crosas and his team sought to circumvent the often-inefficient ubiquitination step, proposing instead a direct delivery mechanism to the proteasome.

In this novel strategy, the researchers engineered small molecule chimeras akin to PROTACs but with an innovative twist: they bypass the ubiquitin tagging entirely, directly guiding tumor-relevant proteins to the proteasome for degradation. The targeted proteins include IMPDH2, a crucial enzyme in nucleotide biosynthesis and cell replication, whose dysregulation is tightly linked to tumor advancement, and CERT1, a lipid transporter protein implicated in the regulation of tumor cell death. This direct targeting approach leverages the proteasome-associated protein USP14, a regulator of proteasome activity, to serve as the docking point for the chimeric molecules.

By binding with high affinity to the target proteins and simultaneously to USP14, these small molecules act as molecular bridges, ushering the proteins straight to the proteasome’s degradation machinery. This method facilitates a streamlined, rapid clearance of proteins essential to tumor growth and survival, effectively crippling the cancer cells’ ability to multiply or evade programmed cell death pathways such as apoptosis. Unlike traditional PROTACs, this approach minimizes reliance on the ubiquitin-proteasome axis’s intermediate steps, thereby mitigating points of failure and inefficiency.

Experimental models using cancer cell lines have demonstrated compelling efficacy of these novel chimeric molecules. Notably, the research revealed that degradation of CERT1 sensitizes tumors to chemotherapy agents, suggesting the restoration of drug susceptibility in resistant cancer types. Resistance to chemotherapy poses a significant clinical challenge, with strikingly high prevalence rates—from 60% to 90% in some carcinomas—and often heralds poor patient prognoses, especially in metastatic disease. This novel approach holds promise to circumvent these resistance mechanisms, potentially rejuvenating the effectiveness of existing chemotherapy regimens.

In discussing the implications, Bernat Crosas emphasized the transformative potential of this technology: by redirecting cellular waste disposal pathways more efficiently, it opens exciting therapeutic avenues where targeted degradation can be tailored to specific proteins driving disease progression. Moreover, the modularity of these chimeric molecules allows for customization to target a broader spectrum of pathological proteins beyond those studied, anticipating applications not only in oncology but also in other diseases defined by aberrant protein function.

The current phase of the research focuses on refining these molecules to enhance their specificity and potency, alongside extensive testing in more physiologically relevant models. This progression is critical to transition from proof of concept to clinical translation, offering a new weapon in the oncologist’s arsenal against chemoresistance. Furthermore, understanding the detailed molecular interactions between these chimeras, target proteins, and proteasomal regulators will inform future design iterations, potentially improving therapeutic windows and minimizing off-target effects.

This innovative work reflects a significant milestone in the realm of targeted protein degradation technologies, expanding beyond established paradigms to harness the proteasome’s full potential more directly and effectively. As the ubiquitin-independent degradation pathways gain traction, they provide a complementary and possibly superior route for eradicating proteins that standard therapies struggle to neutralize. The revolutionary nature of these findings is poised to inspire a rethinking of drug development strategies focused on protein homeostasis and degradation.

In essence, this research illustrates an elegant exploitation of the cell’s intrinsic proteolytic machinery, turning the proteasome into a highly specific and efficient executor of therapeutic protein turnover. The deliberate modulation of proteasomal activity through USP14 targeting and direct substrate delivery represents a conceptual leap with substantial implications, heralding a new class of anticancer agents potentially capable of overcoming drug resistance and improving patient outcomes.

Notably, the funding sources, including the Spanish Ministry of Science, Innovation and Universities, alongside the European Union’s Next Generation funds channeled through the CSIC Global Health Platform and the Government of Catalonia, highlight the strategic importance ascribed to this line of investigation. This underscores robust institutional and governmental support aimed at addressing critical challenges in global health through cutting-edge science.

As the biomedical community continues to explore and optimize protein degradation technologies, these findings emphasize the importance of multidisciplinary collaboration, marrying synthetic chemistry, molecular biology, and pharmacology. The promising preclinical outcomes presented by the CSIC team resonate as a beacon for future endeavors aimed at transforming incurable cancers into manageable conditions through precision molecular interventions.

The study, published in the reputed journal Nature Communications, stands as a compelling testament to the constant evolution of therapeutic modalities. It invites further exploration into ubiquitin-independent mechanisms, challenging researchers to expand the molecular toolkit available for targeted degradation. Ultimately, this discovery could redefine therapeutic strategies not only in cancer but across a broad spectrum of diseases characterized by aberrant proteins refractory to conventional treatment.

Subject of Research: People

Article Title: Expanding the targeted protein degradation approach with small molecule chimeras directed to the 26S proteasome

News Publication Date: 28-Mar-2026

Web References: http://dx.doi.org/10.1038/s41467-026-71132-5

Keywords: Proteasomal degradation, targeted protein degradation, PROTACs, chemotherapy resistance, ubiquitin–proteasome system, IMPDH2, CERT1, USP14, cancer therapeutics

CircRNAs, a class of non-coding RNAs, have recently ascended to prominence due to their ability to regulate gene expression post-transcriptionally. Unlike traditional linear RNAs, circRNAs form closed loops that lend them stability and resistance to degradation, allowing them to persist longer within cellular contexts. What makes circRNF10 particularly intriguing is its dual mechanism of action, contributing to both degradation of its target and the inhibition of pathways that would otherwise promote tumor growth.

The research highlights a critical interaction between circRNF10 and β-catenin, an essential component of the Wnt signaling pathway, which is notoriously activated in many cancers, including lung adenocarcinoma. The study shows that circRNF10 facilitates the degradation of β-catenin in a targeted manner, thereby reducing its availability within the cell. This reduction is significant because β-catenin accumulation has been correlated with increased cell proliferation and resistance to apoptosis, mirroring the hallmarks of cancer.

Furthermore, the researchers elucidated a novel regulatory circuit mediated by miR-1275 and DKK3, which further influences the activity of β-catenin. miRNAs are known to be crucial in gene regulation, and miR-1275 has been implicated in various signaling pathways related to cancer. By inhibiting DKK3, a known antagonist of the Wnt/β-catenin pathway, circRNF10 enhances the effectiveness of β-catenin degradation. This interplay between circRNF10 and the other molecules not only sheds light on the molecular dynamics within cancer cells but also opens up new avenues for targeted therapies.

In addition to dissecting the mechanisms of β-catenin regulation, the implications of these findings extend to the potential therapeutic strategies that could exploit the circRNA’s ability to modulate such critical pathways. By understanding how circRNF10 functions, researchers can pioneer treatments aimed at restoring the proper regulatory balance within cancerous cells. This approach represents a paradigm shift in cancer therapy, which has traditionally focused on directly targeting cell division or apoptosis pathways.

The study emphasizes the potential of circRNAs as both biomarkers and therapeutic targets in cancer treatment. Given the stability and specificity of circRNAs, they could lead to the development of novel diagnostic tools for early detection of lung adenocarcinoma, allowing for timely intervention. Moreover, therapies designed to manipulate circRNA levels may provide an innovative strategy to overcome resistance often seen with conventional treatments.

As the research into circRNF10 and its role in lung adenocarcinoma progresses, it becomes increasingly clear that this area of study holds tremendous promise for not only understanding cancer biology but also for paving the way toward more effective and personalized treatment modalities. The future of cancer therapeutics may heavily rely on harnessing the unique properties of circRNAs to synergize with existing treatment protocols or to develop novel interventions altogether.

The team’s findings, published in Molecular Cancer, present a comprehensive look at how circRNF10 can serve not only as a regulator but also as a potential target for future cancer therapies. By persisting beyond the scope of conventional linear RNA targets, circRNAs like circRNF10 could revolutionize the landscape of how we approach cancer treatment, emphasizing the need for more research into their roles.

In conclusion, the intricate mechanisms by which circRNF10 sequesters β-catenin highlight the complexity of cancer metabolism and its regulation. The duality of circRNF10’s actions illustrates the potential for exploitation in developing innovative strategies aimed at combating lung adenocarcinoma. As scientists continue to unravel the layers of circRNA functionality, we may witness a breakthrough in not only treatment tactics but in our overarching understanding of cancer.

This study heralds a new chapter in oncology, where molecular intricacies are unveiled and translated into clinical modalities. The journey from bench to bedside has never felt more promising, as researchers like Situ and his colleagues take the initiative in addressing one of the most daunting challenges in medical science today—curbing the relentless advance of cancer.

By closely analyzing the multifaceted roles circRNAs play in oncology, we are on the cusp of untapping a reservoir of potential that could dramatically redefine therapeutic strategies for lung adenocarcinoma and perhaps other malignancies as well.

In the grand tapestry of cancer research, the threads woven by circRNF10 demonstrate that even non-coding RNAs can have profound implications for cellular fate and treatment outcomes. As this field continues to evolve, the hope remains that discoveries such as this will foster more effective, targeted, and less invasive cancer therapies, ultimately leading us to advance closer to conquering this formidable disease.

Subject of Research: The regulatory role of circRNF10 in lung adenocarcinoma through β-catenin modulation.

Article Title: CircRNF10 sequestrates β-catenin by a dual regulatory circuit of direct degradation and a miR-1275/DKK3-mediated inhibition in driver gene-negative lung adenocarcinoma.

Article References: Situ, X., Wang, X., Liao, X. et al. CircRNF10 sequestrates β-catenin by a dual regulatory circuit of direct degradation and a miR-1275/DKK3-mediated inhibition in driver gene-negative lung adenocarcinoma. Mol Cancer 25, 13 (2026). https://doi.org/10.1186/s12943-025-02530-4

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12943-025-02530-4

Keywords: CircRNA, lung adenocarcinoma, β-catenin, miR-1275, DKK3, cancer research, targeted therapy, non-coding RNA.